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Gross alterations in cell energy metabolism underlie manifestations of hereditary OXPHOS (oxidative phosphorylation) diseases, many of which
depend on proportion of mutant mitochondrial DNA (mtDNA) in tissues. An animal model of OXPHOS disease with maternal inheritance of
mitochondrial heteroplasmy might help understanding the peculiarities of abnormal mtDNA distribution and its effect on pre- and postnatal deve-
lopment. Previously we obtainedmice that carry humanmtDNA in some tissues. It co-existed with murine mtDNA (heteroplasmy) and was transmitted
maternally to the progeny of animals developed from zygotes injected with human mitochondria. To analyze the probability of obtaining heteroplasmic
mice we increased the number of experiments with early embryos and obtained more specimens from F1. About 33% of zygotes injected with human
mtDNA developed into post-implantation embryos (7th–13th days). Lower amount of such developed into neonate mice (ca. 21%). Among post-
implantation embryos and in generations F0 and F1 percentages of human mtDNA-carriers were ca. 14–16%. Such percentages are sufficient for
modeling maternally inherited heteroplasmy in small animal groups. More data are needed to understand the regularities of anomalous mtDNA
distribution among cells and tissues andwhether heart andmuscles frequently carrying humanmtDNA in our experiments are particularly susceptible to
heteroplasmy.
© 2006 Elsevier B.V. All rights reserved.Keywords: Energy metabolism; OXPHOS diseases modeling; Human mtDNA; mtDNA transfer; Transgenic mice; Maternal inheritance1. Introduction
Protracted alterations of cellular energy metabolism should
result in cell death. In fact, disintegration of mitochondria that
provide cells with energy is a frequent component of apoptosis.
However, a decrease in energy metabolism may be moderate,
under which condition a cell does not switch to the programmed
death, yet accumulation of energy-starving cells in a tissue or an
organ causes its gradual degeneration. Manifestations of the latter
are evidenced in ageing tissues/organs, but are even more vivid in
case of the so-called OXPHOS diseases (from ‘oxidative phos-
phorylation’). In patients the continuous reduction of mito-
chondrial energy production goes much more rapidly than it
occurs in normal individuals at ageing, hence, symptoms of de-
generation in the most energy-dependent tissues sometimes be-⁎ Corresponding author. Fax: +7 812 2349489.
E-mail address: vadim@biomed.spb.su (V.B. Vasilyev).
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doi:10.1016/j.bbabio.2006.05.021come visible already in infancy, early death being the outcome in
quite a few cases. OXPHOS diseases associatedwithmutations in
mitochondrial DNA (mtDNA) are inherited along the maternal
lineage as a developing mammalian embryo gets the great ma-
jority of its mitochondria, if not all, from the oocyte. Despite that
OXPHOS diseases are known since early 1960s [1], the linkage of
their occurrence to mutations in mtDNA was discovered much
later [2]. Mutations are often fatal for the function of mtDNA as
they result in synthesis of invalid protein subunits of several
respiratory complexes in mitochondria [3,4]. Some aspects of this
hereditary pathology are poorly understood, one of the reasons
being the absence of an adequate animal model for studying the
inborn defects of energy metabolism.
mtDNA may undergo several replications within a cell cycle
and, possibly, due to peculiar segregation of mutant mtDNA
copies during cytokinesis these copies are accumulated in certain
cell lineages. When a cell accumulates the critical concentration
of invalid mtDNA, its energy production becomes insufficient. In
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but the share of mutant copies usually increases or at least remains
the same. Co-existence of wild-type and mutant mtDNAwithin a
cell or a mitochondrion is termed ‘heteroplasmy’ and is a crucial
requirement to an animal model of OXPHOS diseases.
A prospective approach to obtaining such a model seems to be
the introduction of foreign or in vitro modified mtDNA-carrying
mitochondria into murine zygotes. Experiments of this kind
mostly included the delivery of mitochondria of onemurine strain
to oocytes of another [5–8]. We have shown recently that injec-
tion of human mitochondria into mouse zygote results in per-
sistence of foreign mtDNA in the tissues of the animal through its
prenatal and postnatal development [9,10]. Evidence that human
mtDNA is not eliminated from the mouse embryo during its pre-
implantation development had been collected [9,11] by the time
when we confirmed the suggestion that it is transmitted along the
maternal lineage [10,12].
In this way we collected evidence that the two prerequisite
features of OXPHOS diseases, i.e., maternal inheritance and het-
eroplasmy can be reproduced in experiments on mice carrying
humanmtDNA. In our experiments the latter was playing a role of
anomalous mitochondrial genome distributed among the tissues
of a patient with hereditary disorders of energy metabolism.
Tomove further on the way to regulated modeling of OXPHOS
diseases one had to know if there are chances to obtain as many
heteroplasmic animals as one needs and whether there are regu-
larities in occurrence of heteroplasmy in sequential generations.
We collected substantially more data on the early development
of mouse embryos injected with human mtDNA and some addi-
tional data on “human mtDNA/mouse mtDNA” heteroplasmy in
generation F1. Additionally, F2 was obtained with transmitochon-
drial animals in it, which supported our data on maternal inhe-
ritance of heteroplasmy, but the amount of data collected so far is
not sufficient to be included in calculations.
Careful statistical evaluation of the results obtained in this and
previous studies was needed to look for indications at some algo-
rithm of distribution of xenogeneic mtDNA among organs/tis-
sues, at the specific impact of manipulations with murine zygotes
upon the mortality of embryos and neonates, at the existence of
any regularity in occurrence of heteroplasmy in sequential gen-
erations of mice. However, the first and main goal of this work
was to learn: (a) what is the mean quota of surviving animals in
experiments with mtDNA transfer that we and other groups keep
carrying out; (b) what is the share of transmitochondrial animals
(i.e., foreign mtDNA-carriers) that can be obtained at least in the
two first generations. Answering these simple questions would
help us concluding what amount of experimental animals should
be sufficient to make the modeling of maternally inherited OX-
PHOS diseases.
2. Materials and methods
2.1. Isolation of mitochondria
Human mitochondria were isolated from cultured HepG2 cells as described
[10]. Their functional activity evidencing the overall integrity of organelles was
assayed by treatment with MitoTracker Red (Molecular Probes, USA) for 30 min
at +4°C dissolved in PBS (phosphate buffer saline) to the final concentration100 nM. Red fluorescence was viewed under Leica DMRXA (Germany) fluo-
rescent microscope evidencing the integrity of the mitochondrial membranes.
Fertilized murine zygotes were prepared as described in our previous paper
[9].
Humanmitochondria (3–10 pl of suspension) were microinjected using micro-
manipulator into zygotes after the latter had been immersed for 20–40min at 37 °C
into HT6 medium containing cytochalazin B (5 mg /ml). Microinjections were
performed at room temperature using glass injection pipettes with internal diameter
4–6 mm [9]. The subsequent procedure is described in [10]. About 500 human
mitochondria were delivered into a zygote by a microinjection.
To evaluate the effect of manipulation on subsequent development of an em-
bryo some zygotes were microinjected at room temperature with buffer solution
containing no mitochondria and left for culturing at 37 °C along with the others.
2.2. Transplantation of microinjected zygotes to the pseudopregnant mice
Murine zygotes carrying human mitochondria were transplanted to the C57Bl
pseudopregnant mice soon after microinjection of mitochondria. Each female
received 10–15 zygotes transplanted into the oviduct under ether anaesthesia.
Species-specific primers were constructed previously [9]. We selected human
mtDNA site 13959–13976 [13] and murine mtDNA site 13437–13455 [14] as
non-homologous sequences suitable for discriminative analysis. The corres-
ponding human (A) and murine (B) 5′-primers looked as:
A 5′-CCTTCTTACGAGCCAAAA-3′
B 5′-ACTCTTCACACAAACATAA-3′
To construct 3′-primers human mtDNA site 14190–14207 and murine
mtDNA site 13584–13601 were selected. These two sequences are highly
homologous (15 bp of 18 coincide). The corresponding human (A) and murine
(B) 3′-primers looked as:
A 5′-CTGGTTGACCATTGTTTG-3′
B 5′-CTGGGTGATCTTTGTTTG-3′
Details of PCR performance with these primers are described in [10].
2.3. DNA isolation for control
Human nuclear [15] and mitochondrial [16] DNA specimens were purified
from HepG2 cells and used as control. Mouse total DNA to be used as control was
isolated and purified from the liver of animals [17].
2.4. Isolation of DNA from tissues of embryos and neonate animals
Total DNAwas isolated after the lysis of pre-implantation embryos at 2- and
4-blastomere stages [9]. Embryos of post-implantation stages were taken out on
the 7th, 8th, 9th, 10th, 11th and 13th days of intrauterine development after the
females had been sacrificed by dislocation of cervical vertebrae. Lysis of entire
7- to 11-day embryos and isolation of their DNA or isolation of the latter from
organs of 13-day embryos and neonate animals were accomplished as we
described earlier [10].
2.5. Statistical evaluation
For each experimental group sampling fraction of the total number of animals or
embryos in that groupwas calculated. A sampling fraction is the quota of animals or
embryos that carries a feature under examination (e.g., transgenic organisms or
embryos developing to a certain stage). An error was calculated for each sampling
fraction. All values were expressed percent to facilitate elaboration of Results and
Discussion. Significance of the difference between various sampling fractions was
calculated using criterion ζ that is analogous to Student's criterion for binominal
distribution. It was also assayed using χ2, and the precise double-side Fischer's
criterion p [18].
To evaluate the validity of the difference between a sampling fraction and the
general fraction we used criteria ζ and χ2. By general fraction we term a portion of
Fig. 1. In vitro development of embryos in the control and experimental groups.
Table 1
Body masses of mice born after injection of human mitochondria into murine
zygotes (F0) and of their progeny (F1)
Control
group
Body mass (g) on the 7th day Body mass (g) on the 10th day
2.42+0.31 3.08+0.41
F0 Non-transgenic
micea
1.98+0.30b Non-transgenic
mice
2.79+0.41
Human mtDNA
carriers
1.59; 1.63;
1.68
Human mtDNA
carriers
2.33; 2.33;
2.39
F1 Non-transgenic
mice
2.39+0.33c Non-transgenic
mice
3.03+0.40
Human mtDNA
carriers
1.73; 1.78;
1.84; 1.89
Human mtDNA
carriers
2.41; 2.48;
2.49; 2.55
a Animals in whose tissues no human mtDNAwas detected.
b Mean of 16 separate values (for details, see Results).
c Mean of 29 separate values.
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the experiments of such kind (i.e., at infinitely large sampling).
“Survival curves” in various experimental and control groups were
compared by method of Mantel/Haenzel [19]. Calculation of the values for
precise double-side Fischer's criterion was accomplished using computer prog-
ram StatXact-4.
3. Results
21 zygote of 73 microinjected with human mitochondria de-
veloped to blastocysts when cultured in vitro, which is 28.8±
5.3% (see Fig. 1). In the control group where zygotes were left
intact prior to culturing 19 embryos of 34 reached the blastocyst
stage, which is 55.9±8.5%. The difference between the shares of
blastocysts in the control and experimental groups is significant at
1% level (ζN2.58, χ2=7.4, P=0.099).
After injecting PBS into 27 zygotes 8 of those developed to
blastocysts (see Fig. 1), which is 29.6±8.8%. The difference
between this and the control group was significant at 5% level
(ζN1.96, χ2 =4.5, P=0.04).
In all early-stage embryos developing after a microinjection
with human mitochondria PCR would reveal human mtDNA. It
is worth noticing that examination of separate blastomeres
showed that not each of those contained human mtDNA. For
example, of 156 embryos analyzed at the 2-blastomere stage in
102 human mtDNA was detected in both cells, while in 54 it
was contained only in one blastomere. All blastocysts
developed from microinjected zygotes contained human
mtDNA.
Human mtDNA was revealed by PCR also in the tissues of
mouse embryos on the 7th–13th day of the intrauterine deve-
lopment. Upon microinjection with human mitochondria 270
murine zygotes were transplanted to 23 pseudopregnant mice,
which allowed obtaining 89 post-implantation embryos. HumanmtDNAwas detected in 13 of those, which is 14.6±3.7%. The
same samples contained also murine mtDNA as revealed by
PCR with mouse mtDNA-specific primers (see Materials and
methods).
In subsequent experiments 105 mouse zygotes into which
human mitochondria had been injected were transplanted to
8 pseudopregnant mice. The total litter contained 22 animals
of which 8 died soon after birth. Organs/tissues were
sampled from 18 neonate mice either on the day of their
death or on the 10th day after birth when the animals were
sacrificed. In three animals human mtDNA was found. All
three were analyzed on the 10th day after birth and it seems
important that their size and weight were noticeably lower
than those of the littermates with no human mtDNA (Table 1;
Fig. 2).
Fig. 2. Two of the three transmitochondrial mice in F0 and their littermate that carried no human mtDNA. The difference in size among the animals is illustrated by the
color schemes corresponding to their body surface.
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which human mitochondria had been injected 29 animals were
analyzed by PCR. Human mtDNA was found in four animals,
which is 13.8±6.4%. However, it is worth noticing that the shares
of transgenic animals in different progenies varied. One line
contained two transgenic mice of ten born by the same female. If
the proportion of transmitochondrial animals is calculated only
for this progeny it will be 20.0±12.7%. Another line contained
four mice in F1, two of whom carried human mtDNA. In the next
generation (F2) of the same line three of five animals belonging to
the progeny of the same female were carrying human mtDNA.
Meanwhile, not a single animal in other lines was carrying human
mtDNA.Table 2
Findings of human mtDNA in various tissues of 13-day mouse embryos and
mice in F0–F2
Organ/tissue 13-day embryos Mice in F0 Mice in F1 Mice in F2 Total
Heart 2 2 2 1 7
Skeletal
muscles
1 2 2 – 5
Stomach – 1 1 1 3
Lungs – – 2 – 2
Brain – 1 1 – 2
Ovaries – – 2 – 2
Testicles – 1 – – 1
Bladder – 1 – – 1
Kidneys – – 1 – 1
Liver – – – 1 1
Uterus – – 1 – 1
Intestine 1a – – – 1
a Anatomical discrimination between stomach and intestine in 13-day embryos
was not always precise, therefore, this finding may be equally attributed either to
stomach or to intestine.HumanmtDNAwas unevenly distributed among the organs of
10-day mice that developed from zygotes injected with human
mitochondria (F0). One animal carried foreign mtDNA in heart
and skeletal muscles, the second had it in heart and testicles, in the
third mouse it was detected in brain, bladder, skeletal muscles and
stomach (Table 2).
The first transmitochondrialmouse of F1 carried humanmtDNA
in heart, skeletal muscles, stomach, ovaries, lungs and kidneys. In
the second animal it was detected only in ovaries and the third one
carried it only in heart. Meanwhile the fourth mouse had human
mtDNA in brain, lungs, uterus and skeletal muscles.
The three transgenic animals of F2 carried human mtDNA in
one organ each, i.e., in heart, stomach and liver.
It should be mentioned that in the 13-day embryos human
mtDNAwas also found in heart, skeletal muscles and in digestive
tract.
4. Discussion
Percentage of mouse embryos developed without malforma-
tions and in due time from intact zygotes was compared to the
respective proportions of embryos in the groupwhere zygotes had
been injected with human mitochondria and in that with sham
injections of PBS. Histogram in Fig. 1 shows that proportions of
normally developing embryos were lower (ca. 80%) in the groups
of both mitochondria- and PBS-injected zygotes than in the con-
trol group (ca. 90%) already on the third day. This difference
becomes highly significant by the stage of blastocyst. We have
shown previously [10] that about 4% of embryos in the two
groups with injections developed to blastocysts some 24 h later
than other 96% and than all the intact embryos in the control
group.
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among the ‘survival curves’ that reflect the pace with which the
number of normally developing embryos decreased at every
developmental stage. Firstly, the group of zygotes injected with
PBS was compared to that in which the ova were injected with
human mitochondria. Since it had been proved that no significant
difference existed between these two groups, we combined the
data and compared the unified group to the control group of intact
zygotes. The obtained result χ2=5.15 confirms that the pace of
decrease of the normally developing embryos' number differs
significantly between the control group and the experimental
groups. It should be noticed that using such logics (when data of
similar experiments are combined) in calculations of the precise
double-side Fischer's criterion increases noticeably the signifi-
cance of the difference (P=0,022).
This result confirms our earlier conclusion [10] that microin-
jection itself and the accompanying manipulations rather than the
content of the needle (e.g., humanmitochondria) evoke a decrease
of the percentage of normally developing embryos. It is also in
line with the evidence obtained by another group [20].
We demonstratedmore than once that foreign mtDNA is never
detected in all blastomeres of an early-stage mouse embryo deve-
loping in vitro [9,10]. Our present study together with the pre-
vious data speaks in favor of a possible mosaicism ofmtDNA that
occurs already at the first egg splittings. On the other hand, these
data allow suggesting that xenogeneic mitochondria are distrib-
uted non-randomly at every division of an embryo. The amount of
mitochondria injected was sufficiently high (ca. 102), hence, in
case of their stochastic distribution in the course of an embryo
partition the probability of their distribution among both daughter
cells is very high. Meanwhile, we have shown that of 156 em1-
bryos having undergone the first splitting 54 (which is 34.6±
3.8%) carried humanmtDNA only in one blastomere. This can be
explained either by aggregation of mitochondria in clusters in the
course of zygote splitting, or by the existence of some minimum
threshold amount of foreign organelles that is necessary for their
fixation in a daughter cell. If it was not the first splitting, onemight
speculate on themtDNA segregation bottleneck that prevents free
selection of mitochondrial genome copies during cell division as
those are clustered in nucleoids and attached to the inner mito-
chondrial membrane [21]. That does not seem to be the case, since
foreign mitochondria that we injected into mouse zygotes could
be traced for some 2–3 splittings if tagged with MitoTracker or
another fluorescent probe [9], which indicates that at least their
major part preserved the structural integrity. It remains unclear
whether human organelles could bind to cytoskeleton as described
for the native mitochondria [22–24]. Hence, this mechanism regu-
lating their behavior in the process of egg splitting cannot be relied
upon as an explanation of uneven distribution of human mtDNA
that we observed. Moreover, experiments of another group [25]
demonstrated that shortly after introduction of foreign mitochon-
dria into a cell they do not get united with the native mitochondria
in a common network, but rather co-exist as two homoplasmic
populations of organelles. It seems likely that human mitochon-
dria in our experiments co-existed with murine organelles during
the first splittings. Therefore, it remains unclear whichmechanism
governs their uneven distribution among blastomeres.Of 270 zygotes injected with human mitochondria and trans-
planted to pseudopregnant mice 89 developed to the age of 7–
13 days, which is 33.0±2.9%. This share is close to the per-
centage of embryos that reached the stage of blastocyst when
cultured in vitro upon injection (see Fig. 1). It is also similar to
the share of embryos developed upon injection into mouse zy-
gotes of mitochondria obtained from another murine line, which
was 33% [26].
We suggested that the general set of all embryos surviving after
our manipulations is 33%. To test this hypothesis, we calculated
the significance of the difference between the general set and the
share of embryos developed to blastocysts from zygotes injected
with human mitochondria (28.8±5.3%). Obtained coefficients ζ
and χ2 were so small that our suggestion is not refuted even at
very low levels of significance.
Percentage of embryos that survived an injection of human
mitochondria and developed to term (i.e., to neonate animals) was
21.0±4.0% (22 mice vs. 105 zygotes). With 95% probability
(ζ=1.96) this quota is lower than the percentage of embryos that
survived after injection and developed to 7th–13th day. This can
be explained by an increasedmortality ofmanipulated embryos in
late prenatal development, but also by peculiarities of carrying
the transplanted embryos by each particular female. The fact
that 8 neonate mice died within the first days after birth favor
the first notion. The second one is partly confirmed by the fact
of successful delivery only by four of eight pseudopregnant
mice to whom zygotes were transplanted upon injection of
human mitochondria.
The share of transmitochondrial embryos at the age of 7–
13 days among 270 embryos transplanted to 23 pseudopregnant
mice after injection of human mitochondria into zygotes was
14.6±3.7%, as mentioned above. Basing on this percentage one
can assert that a possible general set of transmitochondrial em-
bryos achieving this stage of development with 95% probability
will be between 7.35% and 21.85% (coefficient ζ=1.96). This
result can be relied upon in case of planning similar experiments.
In those one has all grounds to expect a high probability of ob-
taining transmitochondrial mice even when small groups of ani-
mals are taken. In particular, our data may be useful for correct
modeling the maternally inherited OXPHOS diseases.
Percentage of transmitochondrial mice in F0 was 16.7±8.8%
(3 of 18 animals analyzed). It was 13.8±6.4% in F1 (4 of 29
analyzedmice). These numbers fall within the predicted limits for
the possible value of the general set of transmitochondrial em-
bryos (see above). This is indicative of the probable regularity in
the reproduction of a certain quota of transmitochondrial animals
in similar experiments.
In contrast to 100% blastocysts that carry human mtDNA the
percentage of transmitochondrial embryos by the 7th–13th day of
development goes down to 14.6±3.7%. This share remains more
or less stable both in the neonate animals of F0 (16.7±8.8%) and
inmice of F1 (13.8±6.4%). An apparently quick drop in the share
of transmitochondrial organisms needs a short comment.
Firstly, we did not determine the percentage of cells in a blas-
tocyst that carried foreign mtDNA. Based on our observation that
sometimes not every blastomere in a 2- and 4-cell embryo carries
foreign mtDNA, it can be suggested that not all the cells of a
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used to isolate DNA, one could expect exactly what we observed,
i.e., exclusively positive answer in a test for human mtDNA,
unless the latter is eliminated at an earlier stage of embryo deve-
lopment, which was not the case.
Secondly, part of the cellular mass of a blastocyst containing
foreign mtDNA might not give the origin to tissues/organs of
post-implantational embryo (e.g., they might be used to form
the covering membranes). We cannot speculate on the input of
this factor in our results, since the regularities underlying the
distribution of cells in early prenatal development are poorly
understood.
Lastly, the conservation of a stable quota of imported mtDNA
in generations of cells and organisms can be explained by the
peculiarities of mtDNA segregation through a “bottleneck” [27],
the main events of which take place during oocytes' maturation. It
has been shown that transmission of a quota of imported mtDNA
(that can resist elimination) to the next generation of germline
cells results in appearance of the same or very similar quota in
daughter cells [25]. In our case indirect evidence in favor of the
latter phenomenon is the uneven frequency of transgenic animals
in various murine lineages founded by females developed from
ova injected with human mitochondria. In some lineages no
transmitochondrial mice were revealed either in F1 or F2. In other
lineages human mtDNAwas detected in half of the litter or more
(2 of 4 animals in F1 and 3 of 5 in F2).
However, the bottleneck model proposed by Shoubridge and
collaborators [25] presumes that the stable share of imported
mtDNA (i.e., the percentage of heteroplasmy) should be con-
served virtually in all organs of a transmitochondrial animal. We
were unable to detect foreign mtDNA in all the tissues of trans-
mitochondrial mice, which is not fully in line with that model
basedmainly upon thorough investigation ofmtDNA segregation
in oogenesis [25,27]. One should conclude that more transmi-
tochondrial zygotes and subsequently more embryos are needed
to study the segregation of the heteroplasmy.
Careful examination of the distribution of human mtDNA
among various organs of 10-day mice and in 13-day embryos
allows noticing that the most frequent targets for foreign mtDNA
are heart and skeletal muscles (Table 2). Due to the strong depen-
dence on energy production these organs are mostly affected in
various OXPHOS diseases, but more data are needed to under-
stand whether we observed a coincidence or these tissues are
really more susceptible to heteroplasmy.
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